OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Monk on the Utility of PARP Inhibitors as Maintenance Therapy in Ovarian Cancer

July 28th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Dr. Dreicer on the Clinical Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer

July 28th 2021

Robert Dreicer, MD, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in locally advanced or metastatic urothelial cancer.

Dr. Roboz on Recent Therapeutic Developments in AML

July 27th 2021

Gail J. Roboz, MD, discusses recent therapeutics developments in the treatment of patients with acute myeloid leukemia.

Dr. Rosenberg on the Potential Clinical Implications of the GRIFFIN Trial in Multiple Myeloma

July 27th 2021

Aaron Seth Rosenberg, MD, MS, discusses the potential clinical implications of the phase 2 GRIFFIN trial in multiple myeloma.

Dr. Van Tine on the Rationale to Evaluate Catequentinib in Synovial Sarcoma

July 27th 2021

Brian A. Van Tine, MD, PhD, discusses the rationale to evaluate catequentinib in synovial sarcoma.

Dr. Roeker on the Emerging Role of MRD in CLL

July 27th 2021

Lindsey Roeker, MD, discusses the emerging role of minimal residual disease as a predictive end point in chronic lymphocytic leukemia.

Dr. Shirasu on the Utilization of ctDNA Testing in CRC

July 27th 2021

Hiromichi Shirasu, MD, discusses the utilization of circulating tumor DNA testing in colorectal cancer.

Dr. Gradishar on Integrating Novel Options Into the HER2+ Breast Cancer Treatment Algorithm

July 26th 2021

William Gradishar, MD, discusses factors to consider when determining the optimal treatment of patients with HER2-positive breast cancer.

Dr. Pieczonka on the Rationale to Evaluate VERU-111 in mCRPC

July 26th 2021

Christopher Pieczonka, MD, discusses the rationale to evaluate sabizabulin in men with metastatic castration-resistant prostate cancer in the phase 3 VERACITY trial.

Dr. Smith on the Patient Population of the ECOG-ACRIN E1411 Trial in MCL

July 26th 2021

Mitchell R. Smith, MD, PhD, discusses the patient population of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Dr. Gainor on the Potential Value of Targeting TROP-2 and CEACAM5 in Lung Cancer

July 23rd 2021

Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.

Dr. Gandara on Developments in HER2-Targeted Therapies in NSCLC

July 23rd 2021

David R. Gandara, MD, discusses recent developments in HER2-targeted therapies as a treatment for patients with non-small cell lung cancer.

Dr. Rampal on Selecting Among Available JAK Inhibitors in Myelofibrosis

July 22nd 2021

Raajit K. Rampal, MD, PhD, discusses considerations for selecting among the JAK inhibitors ruxolitinib and fedratinib in the treatment of patients with myelofibrosis.

Dr. Carey on the ​Results of the monarchE Trial in HR+/HER2- Breast Cancer

July 22nd 2021

Lisa A. Carey, MD, FASCO, discusses the phase 3 monarchE trial in hormone receptor–positive, HER2-negative breast cancer.

Dr. Burnham on Closing the Gap in Health Disparities in Prostate Cancer

July 22nd 2021

Leanne Burnham, PhD, discusses the need to close the gap in health disparities in prostate cancer.

Dr. Thompson on Emerging Treatment Strategies With BTK Inhibitors in CLL

July 22nd 2021

Meghan Thompson, MD, discusses emerging treatment strategies with BTK inhibitors in chronic lymphocytic leukemia.

Dr. Basho on the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer

July 22nd 2021

Reva K. Basho, MD, discusses the integration of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr. Pecot on the Growth of Actionable Targets in Lung Cancer

July 22nd 2021

Chad V. Pecot, MD, discusses the growth of actionable targets in lung cancer.

Dr. Sallman on the Efficacy of Pevonedistat Plus Azacitidine in Higher-Risk MDS

July 21st 2021

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

Dr. Pollyea on Emerging Therapies in Higher-Risk Myelodysplastic Syndrome

July 21st 2021

Daniel Pollyea, MD, MS, discusses emerging therapies in higher-risk myelodysplastic syndrome.

NEXT PAGE
PREVIOUS PAGE